Strain Information | |
---|---|
Image | |
BRC No. | RBRC02288 |
Type | Targeted Mutation |
Species | Mus musculus |
Strain name | C57BL/6-St3gal4<tm2Bsi> |
Former Common name | ST34(#4)C57BL/6J, #4 |
H-2 Haplotype | |
ES Cell line | MS12 [C57BL/6] |
Background strain | C57BL/6JJcl |
Appearance | |
Strain development | |
Strain description | ST3 GAL IV conditoinal targeted mouse |
Colony maintenance | |
References |
Health Report | |
---|---|
Examination Date / Room / Rack |
Gene | |||||||
---|---|---|---|---|---|---|---|
Gene Symbol | Gene Name | Chr. | Allele Symbol | Allele Name | Common Names | Promoter | Diseases Related to This Gene |
Frt | yeast FRT (flippase recombination target) site | 9 | Frt | ||||
Frt | yeast FRT (flippase recombination target) site | 9 | Frt | ||||
St3gal4 | ST3 beta-galactoside alpha-2,3-sialyltransferase 4 | 9 | St3gal4 | targeted mutation 2, RIKEN BSI | |||
loxP | phage P1 loxP | 9 | loxP | ||||
loxP | phage P1 loxP | 9 | loxP | ||||
neo | neomycin resistance gene (E. coli) | 9 | mouse phosphoglycerate kinase promoter (PGK promoter) |
Phenotype | |
---|---|
Annotation by Mammalian phenotyhpe ontology | |
Detailed phenotype data |
Ordering Information | |
---|---|
Donor DNA | マウス ST3Gal IV, P1 ファージ loxP, 酵母 FRT, E. coli ネオマイシン耐性遺伝子 |
Research application | Cre/loxP system General Purpose Metabolism Research |
Specific Term and Conditions | The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. 1. The RECIPIENT agrees to use BIOLOGICAL RESOURCE only for academic research which is expected to be publicized in scientific papers. 2. The RECIPIENT will obtain a prior written consent on the use of BIOLOGICAL RESOURCE from the DEPOSIOR/DEVELOPER. At the same time, the RECIPENT will give the DEPOSITOR/DEVELOPER the details of the research project using BIOLOGICAL RESOURCE for the DEPOSITOR/DEVELOPER to determine whether research collaboration is appropriate. 3. If the DEPOSITOR/DEVELOPER determines that the informed research project requires collaboration, a separate agreement will be formulated by both parties to establish rules such as handling of the research results. 4. If the DEPOSITOR/DEVELOPER determines that the informed research project does not require collaboration, the RECIPIENT agrees to cite the literatire(s) designated by the DEPOSITOR/DEVEVLOPER when publicizing the research results obtained from use of BIOLOGICAL RESOURCE, and to discuss with the DEPOSITOR/DEVELOPER when application for any patents is considered. 5. If the RECIPIENT wants to crossbreed BIOLOGICAL RESOURCE with other genetically engineered mice, the RECIPIENT will obtain a prior written consent from the DEPOSITOR/DEVELOPER. 6. The RECIPIENT will not distribute the BIOLOGICAL RESOURCE to any other individual or entity. |
Depositor | Yoshio Hirabayashi (RIKEN) |
Strain Status | Frozen embryos |
Strain Availability | Recovery and QC required prior to distribution |
Additional Info. | Necessary documents for ordering: |
BRC mice in Publications |
---|
No Data |